MarketCapExport financials
BIOLASE (BIOL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
BIOLASE Income Statement 2023-2008 | BIOL
Brief overview of financial results at BIOLASE
The figures are compared over a five-year interval. Revenue at BIOLASE moved from 46.2 million dollars in 2018 to 49.2 million dollars in 2023. The five-year change reached +6.5%, while CAGR stood at 1.3%. Sales changed only slightly and remained broadly flat.
Gross profit was 16.9 million dollars at the start and 16.7 million dollars at the end of the period (−1%). Cost of revenue moved broadly in line with sales. The gross margin was 36.6% at the start and 34% at the end. The contraction points to pressure from direct costs or weaker pricing power.
EBITDA changed from −19.9 million dollars to −15.1 million dollars (+24.1%). EBITDA grew faster than revenue, indicating positive operating leverage. Comparing the endpoints gives EBITDA margins of −43.2% and −30.8%. Higher profitability strengthens the quality of operating growth.
Across the five years, the net result shifted from −$21.5 million to −$20.6 million. The negative result improved without reaching break-even.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are higher operating efficiency and consistent net profitability. The most visible risks are a lower gross margin, a narrow EBITDA buffer and limited revenue growth. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement BIOLASE
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
192 K | 26.2 K | 546 K | 69.1 M | 348 M | 937 M | 774 M | 2.37 B | 6.84 B | 13.5 B | 9.86 B | 10.1 B | 11.4 B | - | - | - |
Shares |
1.28 M | 69 K | 59 K | 2.44 M | 23.2 M | 20.6 M | 14.8 M | 12.1 M | 58.2 M | 42.2 M | 32.8 M | 32.2 M | 30.6 M | 26.2 M | 25.4 M | - |
Historical Prices |
0.15 | 0.38 | 9.25 | 28.2 | 15 | 45.5 | 52.5 | 195 | 118 | 320 | 301 | 314 | 372 | - | - | - |
Net Income |
-20.6 M | -28.6 M | -16.2 M | -16.8 M | -17.9 M | -21.5 M | -16.9 M | -15.4 M | -20.3 M | -18.9 M | -11.5 M | -3.06 M | -4.49 M | -12 M | -2.96 M | - |
Revenue |
49.2 M | 48.5 M | 39.2 M | 22.8 M | 37.8 M | 46.2 M | 46.9 M | 51.8 M | 48.5 M | 47.7 M | 56.4 M | 57.4 M | 48.9 M | - | - | - |
Cost of Revenue |
32.4 M | 32.6 M | 22.7 M | 16.6 M | 23.5 M | 29.3 M | 31.8 M | 31.5 M | 32.5 M | 29.5 M | 34.9 M | 30.9 M | 27.5 M | 17.4 M | 23.3 M | - |
Gross Profit |
16.7 M | 15.9 M | 16.5 M | 6.17 M | 14.3 M | 16.9 M | 15.1 M | 20.3 M | 16 M | 18.2 M | 21.5 M | 26.5 M | 21.3 M | 8.82 M | 20.1 M | - |
Operating Income |
-17.9 M | -25.3 M | -16.4 M | -18.5 M | -15.6 M | -20.9 M | -18 M | -15 M | -19.9 M | -17.9 M | -11 M | -2.53 M | -4 M | -11.5 M | -2.96 M | - |
Interest Expense |
- | - | - | - | - | -1 K | 42 K | 70 K | 74 K | - | -27 K | 239 K | 305 K | 361 K | 58 K | - |
EBITDA |
-15.1 M | -24.8 M | -16 M | -18 M | -14.6 M | -19.9 M | -16.8 M | -13.9 M | -19 M | -17.2 M | -10.4 M | -2.02 M | -3.31 M | -10.4 M | -1.52 M | - |
Operating Expenses |
34.7 M | 41.2 M | 33 M | 24.7 M | 29.9 M | 37.8 M | 33.2 M | 35.3 M | 35.9 M | 36.1 M | 32.5 M | 29 M | 25.3 M | 20.3 M | 23 M | - |
General and Administrative Expenses |
10.2 M | 12.3 M | 11.3 M | 9.77 M | 10.7 M | 11.8 M | 9.71 M | 10.5 M | 10.3 M | 14.9 M | 9.38 M | 8.08 M | 7.94 M | 6.56 M | 7.84 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement BIOLASE
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
36.1 M | 33.4 M | 17.8 M | 3.42 M | 1.18 M | 545 K | 32.8 M | 77 K | 7.62 M | 6.19 M | 6.16 M | 6.15 M | 152 M | 151 M | 135 M | 97.7 M | 81.3 M | 38 M | 31.5 M | 31.4 M | 21.9 M | 21.6 M | 21.1 M | 22 M | 20.6 M | 20.5 M | 102 M | 20.5 M | 76 M | 67.8 M | 67.6 M | 67.6 M | 58.6 M | 58.3 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 58.1 M | 37.4 M | 42.4 M | 37.6 M | 36.5 M | 37.4 M | 32.4 M | 31.7 M | 31.5 M | 31.3 M | 31.2 M | 31 M | 30.7 M | 30.5 M | 30.2 M | 28.1 M | 27.3 M |
Net Income |
-1.43 M | -2.8 M | -6.48 M | - | -4.59 M | -4.87 M | -5.85 M | - | -8.39 M | -5.61 M | -4.78 M | - | -3.28 M | -702 K | -6.9 M | - | 12 K | -4.7 M | -6.01 M | - | -5.48 M | -3.9 M | -4.9 M | - | -4.66 M | -4.91 M | -5.02 M | - | -4.61 M | -4.29 M | -4.11 M | - | -3.15 M | -3.53 M | -4.26 M | - | -5.34 M | -7.04 M | -5.44 M | - | -3.5 M | -6.44 M | -4.89 M | - | -4.05 M | -2.57 M | -2.63 M | - | -548 K | -1.88 M | -1.67 M | - | -953 K | -753 K | -750 K |
Revenue |
10.8 M | 11.6 M | 10.1 M | - | 10.9 M | 14.3 M | 10.5 M | - | 12 M | 12.2 M | 10.2 M | - | 9.53 M | 9.13 M | 8.12 M | - | 6.54 M | 2.94 M | 4.78 M | - | 8.65 M | 8.64 M | 10.3 M | - | 10.9 M | 12.2 M | 10 M | - | 10.8 M | 12.6 M | 10.9 M | - | 13.2 M | 13.8 M | 11 M | - | 11.2 M | 11.9 M | 10.9 M | - | 12.7 M | 10.2 M | 11.5 M | - | 12.3 M | 14.2 M | 14.6 M | - | 13.8 M | 12.2 M | 12.3 M | - | 13.1 M | 12.1 M | 10.6 M |
Cost of Revenue |
6.47 M | 6.95 M | 6.8 M | - | 7.18 M | 8.17 M | 7.13 M | - | 9.56 M | 7.09 M | 5.44 M | - | 4.69 M | 5.09 M | 5.38 M | - | 4.26 M | 2 M | 3.43 M | - | 5.68 M | 5.26 M | 6.8 M | - | 7 M | 7.85 M | 6.99 M | - | 7.95 M | 7.91 M | 6.92 M | - | 7.62 M | 8.15 M | 7.37 M | - | 7.85 M | 8.17 M | 7.64 M | - | 7.32 M | 6.46 M | 1.3 M | - | 8.52 M | 8.69 M | - | - | 7.5 M | 7.82 M | 6.51 M | - | 7.74 M | 6.47 M | 5.72 M |
Gross Profit |
4.38 M | 4.61 M | 3.34 M | - | 3.75 M | 6.12 M | 3.34 M | - | 2.44 M | 5.14 M | 4.73 M | - | 4.84 M | 4.04 M | 2.74 M | - | 2.27 M | 941 K | 1.35 M | - | 2.97 M | 3.38 M | 3.52 M | - | 3.94 M | 4.31 M | 3.03 M | - | 2.86 M | 4.7 M | 3.95 M | - | 5.6 M | 5.66 M | 3.64 M | - | 3.38 M | 3.7 M | 3.21 M | - | 5.39 M | 3.73 M | 3.94 M | - | 3.83 M | 5.56 M | 5.79 M | - | 6.28 M | 5.5 M | 5.81 M | - | 5.32 M | 5.61 M | 4.84 M |
Operating Income |
-695 K | -3.22 M | -4.53 M | - | -3.7 M | -3.87 M | -5.29 M | - | -7.65 M | -5.06 M | -4.21 M | - | -2.66 M | -3.28 M | -6.06 M | - | -3.67 M | -3.98 M | -5.35 M | - | -4.88 M | -3.34 M | -4.36 M | - | -4.51 M | -4.68 M | -5.18 M | - | -4.76 M | -4.48 M | -4.08 M | - | -3.15 M | -3.39 M | -4.31 M | - | -5.35 M | -7.03 M | -5.26 M | - | -3.3 M | -6.19 M | -4.64 M | - | -3.86 M | -2.29 M | -2.82 M | - | -388 K | -1.71 M | -1.62 M | - | -938 K | -717 K | -406 K |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | 1 K | - | 29 K | 1 K | 1 K | - | 29 K | 19 K | 9 K | - | 52 K | 33 K | 16 K | - | 44 K | 23 K | - | - | - | -15 K | - | - | - | - | - | - | 98 K | 38 K | 5 K | - | 2 K | 6 K | 73 K |
EBITDA |
1.26 M | -1.91 M | -3.87 M | - | -1.56 M | -2.3 M | -5.14 M | - | -7.28 M | -4.81 M | -4.09 M | - | -2.38 M | -3.11 M | -5.98 M | - | -3.14 M | -3.49 M | -5.18 M | - | -4.13 M | -2.81 M | -4.11 M | - | -3.8 M | -4.17 M | -4.92 M | - | -3.87 M | -3.9 M | -3.79 M | - | -2.37 M | -2.9 M | -4.1 M | - | -4.76 M | -6.7 M | -5.1 M | - | -2.77 M | -5.84 M | -4.46 M | - | -3.42 M | -1.99 M | -2.67 M | - | -15 K | -1.47 M | -1.5 M | - | -376 K | -306 K | -178 K |
Operating Expenses |
5.08 M | 7.83 M | 7.86 M | - | 7.44 M | 9.99 M | 8.63 M | - | 10.1 M | 10.2 M | 8.94 M | - | 7.5 M | 7.32 M | 8.8 M | - | 5.94 M | 4.92 M | 6.7 M | - | 7.85 M | 6.72 M | 7.89 M | - | 8.45 M | 8.99 M | 8.22 M | - | 7.62 M | 9.18 M | 8.03 M | - | 8.75 M | 9.04 M | 7.96 M | - | 8.73 M | 10.7 M | 8.47 M | - | 8.69 M | 9.92 M | 8.58 M | - | 7.69 M | 7.85 M | 8.61 M | - | 6.67 M | 7.21 M | 7.43 M | - | 6.26 M | 6.33 M | 5.24 M |
General and Administrative Expenses |
1.28 M | 3.06 M | 3.2 M | - | 2.68 M | 2.36 M | 2.46 M | - | 3.11 M | 3.14 M | 2.58 M | - | 2.48 M | 2.78 M | 3.45 M | - | 2.3 M | 2.14 M | 3.01 M | - | 3.21 M | 2.51 M | 2.39 M | - | 2.68 M | 2.97 M | 3.04 M | - | 2.02 M | 2.84 M | 2.42 M | - | 2.78 M | 2.66 M | 2.27 M | - | 2.86 M | 3.92 M | 2.59 M | - | 3.47 M | 5.31 M | 3.08 M | - | 2.46 M | 2.6 M | 2.25 M | - | 1.84 M | 2.22 M | 2.21 M | - | 1.99 M | 2.23 M | 1.7 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company BIOLASE (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |